Processa Pharmaceuticals Inc (PCSA)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Processa Pharmaceuticals Inc released operating deficit of $-6.057118 million, in the third quarter of 2022 financial report
PCSA recorded third quarter of 2022 operating deficit of $-6.057118 million
Published Nov 28 2022
CSIMarket Team / CSIMarket.com
Following the large companies in the Major Pharmaceutical Preparations industry, some overlooked entities are publishing the earnings. PCSA mentioned it has clinched operating deficit of $-6.057118 million, for the third quarter of 2022.
The operating deficit has depleted from $-3.459797 million, from the third quarter of 2021. But more importantly, the market observers are speculating, when the PCSAs' could begin to cite the revenue.
It is not really a surprise, that the small company recorded a net loss of $-6.020 million, that has widen from $-3.157 million, in third quarter of 2021.
Processa Pharmaceuticals Inc is expected to report next financial results on May 01, 2023.
The operating deficit has depleted from $-3.459797 million, from the third quarter of 2021. But more importantly, the market observers are speculating, when the PCSAs' could begin to cite the revenue.
It is not really a surprise, that the small company recorded a net loss of $-6.020 million, that has widen from $-3.157 million, in third quarter of 2021.
Processa Pharmaceuticals Inc is expected to report next financial results on May 01, 2023.